Gilead Shot Provides Total Protection From HIV in Trial of Young African Women An injection given just twice a year could herald a breakthrough in protecting the population that has the highest infection rates.

How Gilead Profited by Slow-Walking a Promising H.I.V. Therapy Gilead delayed a new version of a drug, allowing it to extend the patent life of a blockbuster line of medications, internal documents show.